(Q53162022)

English

N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.

scientific article published on 2 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

1 reference

based on heuristic

inferred from title

obsessive-compulsive disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

K Paydary

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

A Akamaloo

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

A Ahmadipour

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

F Pishgar

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

S Emamzadehfard

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

S Akhondzadeh

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

publication date

2 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

Journal of Clinical Pharmacy and Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

41

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

214-219

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

Obsessive compulsive disorder and the glutamatergic system

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Glutathione: a novel treatment target in psychiatry

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Decreased thalamic glutamate level in unmedicated adult obsessive-compulsive disorder patients detected by proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Glutamatergic dysfunction in OCD.

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

The promise of N-acetylcysteine in neuropsychiatry

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial.

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Brain-behavior relationships in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Effects of ketamine in treatment-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

A.E. Bennett Research Award. Toward a neurodevelopmental model of of obsessive--compulsive disorder

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12370

21 January 2018

Identifiers

10.1111/JCPT.12370

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26931055

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53162022&oldid=1512284761"